The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. The company lost $26.6 million in the first half of ...
The company's lead drug Azelaprag has been well-tolerated in 265 individuals across eight Phase 1 trials. The STRIDES clinical trial will assess azelaprag with Eli Lilly's Zepbound, with topline ...
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 ...
Some results have been hidden because they may be inaccessible to you